
Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA
- Author
- Vanessa Vermeirssen (UGent) , Jill Deleu (UGent) , Annelien Morlion (UGent) , Celine Everaert (UGent) , Jilke De Wilde (UGent) , Jasper Anckaert (UGent) , Kaat Durinck (UGent) , Justine Nuytens (UGent) , Muhammad Rishfi (UGent) , Franki Speleman (UGent) , Hanne Van Droogenbroeck (UGent) , Kimberly Verniers (UGent) , MF Baietti, M Albersen, E Leucci, E Post, MG Best, Tom Van Maerken (UGent) , Bram De Wilde (UGent) , Jo Vandesompele (UGent) and Anneleen Decock (UGent)
- Organization
- Project
-
- Cancer-specific circulating RNAs as biomarkers for diagnosis and therapy response monitoring
- Scrutinizing selective Aurora Kinase A inhibition as a novel entry point for synthetic lethality in neuroblastoma
- The biology of tumor-derived extracellular RNA in liquid biopsies
- Development of a fast, minimally-invasive and affordable test for accurate diagnosis of Cancer of Unknown Primary (CUP) using DNA methylation profiling.
- Exploring the use of extracellular RNA in liquid biopsies for precision oncology purposes
- Replicative stress resistance modelling and therapeutic targeting in neuroblastoma
- Replication fork protector dependency factors: novel targets for combination treatment and immunomodulation in neuroblastoma (REINFORCE)
- Therapy response monitoring in pediatric cancer basket trial patients
- Abstract
- While cell-free DNA (cfDNA) is widely being investigated, free circulating RNA (extracellular RNA, exRNA) has the potential to improve cancer therapy response monitoring and detection due to its dynamic nature. However, it remains unclear in which blood subcompartment tumour-derived exRNAs primarily reside. We developed a host-xenograft deconvolution framework, exRNAxeno, with mapping strategies to either a combined human-mouse reference genome or both species genomes in parallel, applicable to exRNA sequencing data from liquid biopsies of human xenograftmousemodels. The tool enables to distinguish (human) tumoural RNA from (murine) host RNA, to specifically analyse tumour-derived exRNA. We applied the combined pipeline to total exRNA sequencing data from 95 blood-derived liquid biopsy samples from 30 mice, xenografted with 11 different tumours. Tumoural exRNA concentrations are not determined by plasma platelet levels, while host exRNA concentrations increase with platelet content. Furthermore, a large variability in exRNA abundance and transcript content across individual mice is observed. The tumoural gene detectability in plasma is largely correlated with the RNA expression levels in the tumour tissue or cell line. These findings unravel new aspects of tumour-derived exRNA biology in xenograftmodels and open new avenues to further investigate the role of exRNA in cancer.
- Keywords
- CANCER, PDX
Downloads
-
zcac037.pdf
- full text (Published version)
- |
- open access
- |
- |
- 1.02 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01GKHPA0K5M1ZCKX0SZQ83DB3D
- MLA
- Vermeirssen, Vanessa, et al. “Whole Transcriptome Profiling of Liquid Biopsies from Tumour Xenografted Mouse Models Enables Specific Monitoring of Tumour-Derived Extracellular RNA.” NAR CANCER, vol. 4, no. 4, 2022, doi:10.1093/narcan/zcac037.
- APA
- Vermeirssen, V., Deleu, J., Morlion, A., Everaert, C., De Wilde, J., Anckaert, J., … Decock, A. (2022). Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA. NAR CANCER, 4(4). https://doi.org/10.1093/narcan/zcac037
- Chicago author-date
- Vermeirssen, Vanessa, Jill Deleu, Annelien Morlion, Celine Everaert, Jilke De Wilde, Jasper Anckaert, Kaat Durinck, et al. 2022. “Whole Transcriptome Profiling of Liquid Biopsies from Tumour Xenografted Mouse Models Enables Specific Monitoring of Tumour-Derived Extracellular RNA.” NAR CANCER 4 (4). https://doi.org/10.1093/narcan/zcac037.
- Chicago author-date (all authors)
- Vermeirssen, Vanessa, Jill Deleu, Annelien Morlion, Celine Everaert, Jilke De Wilde, Jasper Anckaert, Kaat Durinck, Justine Nuytens, Muhammad Rishfi, Franki Speleman, Hanne Van Droogenbroeck, Kimberly Verniers, MF Baietti, M Albersen, E Leucci, E Post, MG Best, Tom Van Maerken, Bram De Wilde, Jo Vandesompele, and Anneleen Decock. 2022. “Whole Transcriptome Profiling of Liquid Biopsies from Tumour Xenografted Mouse Models Enables Specific Monitoring of Tumour-Derived Extracellular RNA.” NAR CANCER 4 (4). doi:10.1093/narcan/zcac037.
- Vancouver
- 1.Vermeirssen V, Deleu J, Morlion A, Everaert C, De Wilde J, Anckaert J, et al. Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA. NAR CANCER. 2022;4(4).
- IEEE
- [1]V. Vermeirssen et al., “Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA,” NAR CANCER, vol. 4, no. 4, 2022.
@article{01GKHPA0K5M1ZCKX0SZQ83DB3D, abstract = {{While cell-free DNA (cfDNA) is widely being investigated, free circulating RNA (extracellular RNA, exRNA) has the potential to improve cancer therapy response monitoring and detection due to its dynamic nature. However, it remains unclear in which blood subcompartment tumour-derived exRNAs primarily reside. We developed a host-xenograft deconvolution framework, exRNAxeno, with mapping strategies to either a combined human-mouse reference genome or both species genomes in parallel, applicable to exRNA sequencing data from liquid biopsies of human xenograftmousemodels. The tool enables to distinguish (human) tumoural RNA from (murine) host RNA, to specifically analyse tumour-derived exRNA. We applied the combined pipeline to total exRNA sequencing data from 95 blood-derived liquid biopsy samples from 30 mice, xenografted with 11 different tumours. Tumoural exRNA concentrations are not determined by plasma platelet levels, while host exRNA concentrations increase with platelet content. Furthermore, a large variability in exRNA abundance and transcript content across individual mice is observed. The tumoural gene detectability in plasma is largely correlated with the RNA expression levels in the tumour tissue or cell line. These findings unravel new aspects of tumour-derived exRNA biology in xenograftmodels and open new avenues to further investigate the role of exRNA in cancer.}}, author = {{Vermeirssen, Vanessa and Deleu, Jill and Morlion, Annelien and Everaert, Celine and De Wilde, Jilke and Anckaert, Jasper and Durinck, Kaat and Nuytens, Justine and Rishfi, Muhammad and Speleman, Franki and Van Droogenbroeck, Hanne and Verniers, Kimberly and Baietti, MF and Albersen, M and Leucci, E and Post, E and Best, MG and Van Maerken, Tom and De Wilde, Bram and Vandesompele, Jo and Decock, Anneleen}}, issn = {{2632-8674}}, journal = {{NAR CANCER}}, keywords = {{CANCER,PDX}}, language = {{eng}}, number = {{4}}, pages = {{14}}, title = {{Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA}}, url = {{http://doi.org/10.1093/narcan/zcac037}}, volume = {{4}}, year = {{2022}}, }
- Altmetric
- View in Altmetric